Pharmaceutical Manufacturing Handbook: Production and

650 NASAL DELIVERY OF PEPTIDE AND NONPEPTIDE DRUGS
228. Aguilar , J. C. , Lobaina , Y. , Muzio , V. , Garcia , D. , Penton , E. , Iglesias , E. , Pichardo , D. ,
Urquiza , D. , Rodeiguez , D. , Silva , D. , Petrovsky , N. , and Guillen , G. ( 2004 ), Development
of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B
core antigen to stimulate a strong Th1 response against hepatitis B surface antigen ,
Immnol. Cell. Biol. , 82 , 539 – 546 .
229. Hordness , K. , Tynning , T. , Brown , T. A. , Haneberg , B. , and Jonsson , R. ( 1997 ), Nasal
immunization with group B streptococci can induce high levels of specifi c IgA antibodies
in cervicovaginal secretions of mice , Vaccine , 15 , 1244 – 1251 .
230. Kurono , Y. , Yamamoto , M. , Fujihashi , K. , Kodama , S. , Suzuki , M. , Mogi , G. , McGhee ,
J. R. , and Kiyono , H. ( 1991 ), Nasal immunization induces Haemophilis infl uenzae -
specifi c Th1 and Th2 responses with mucosal IgA and systemic IgG antibodies for protective
immunity , J. Infect. Dis. , 180 , 122 – 132 .
231. Hagiwara , Y. , Komase , K. , Chen , Z. , Matsuo , K. , Suzuki , Y. , Aizawa , C. , Kurata , T. , and
Tamura , S. ( 1999 ), Mutants of cholera toxin as an effective and safe adjuvant for nasal
infl uenza vaccine , Vaccine , 17 , 2918 – 2926 .
232. Bastein , N. , Trudel , M. , and Simard , C. ( 1999 ), Complete protection of mice from respiratory
syncytial virus infection following mucosal delivery of synthetic peptide vaccines ,
Vaccine , 17 , 832 – 836 .